You are here

Nat Nanotechnol DOI:10.1038/s41565-022-01179-0

Nanozyme-catalysed CRISPR assay for preamplification-free detection of non-coding RNAs.

Publication TypeJournal Article
Year of Publication2022
AuthorsBroto, M, Kaminski, MM, Adrianus, C, Kim, N, Greensmith, R, Dissanayake-Perera, S, Schubert, AJ, Tan, X, Kim, H, Dighe, AS, Collins, JJ, Stevens, MM
JournalNat Nanotechnol
Date Published2022 Aug 04
ISSN1748-3395
Abstract

CRISPR-based diagnostics enable specific sensing of DNA and RNA biomarkers associated with human diseases. This is achieved through the binding of guide RNAs to a complementary sequence that activates Cas enzymes to cleave reporter molecules. Currently, most CRISPR-based diagnostics rely on target preamplification to reach sufficient sensitivity for clinical applications. This limits quantification capability and adds complexity to the reaction chemistry. Here we show the combination of a CRISPR-Cas-based reaction with a nanozyme-linked immunosorbent assay, which allows for the quantitative and colorimetric readout of Cas13-mediated RNA detection through catalytic metallic nanoparticles at room temperature (CrisprZyme). We demonstrate that CrisprZyme is easily adaptable to a lateral-flow-based readout and different Cas enzymes and enables the sensing of non-coding RNAs including microRNAs, long non-coding RNAs and circular RNAs. We utilize this platform to identify patients with acute myocardial infarction and to monitor cellular differentiation in vitro and in tissue biopsies from prostate cancer patients. We anticipate that CrisprZyme will serve as a universally applicable signal catalyst for CRISPR-based diagnostics, which will expand the spectrum of targets for preamplification-free, quantitative detection.

DOI10.1038/s41565-022-01179-0
Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35927321?dopt=Abstract

Alternate JournalNat Nanotechnol
PubMed ID35927321